Results 101 to 110 of about 402,092 (282)

Vestibular Patient Journey: Insights From Vestibular Disorders Association (VeDA) Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Vestibular symptoms impose a high burden of disability. Understanding real‐world diagnostic and treatment pathways can identify care gaps and guide interventions. We aimed to characterize symptom profiles, diagnostic trends, provider involvement, and treatment patterns in vestibular disorders.
Ali Rafati   +10 more
wiley   +1 more source

Comments on “Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project” [Letter]

open access: yesClinical Epidemiology
Fitri Rokhmalia,1 Dwi Krihariyani,2 Sari Luthfiyah,3 T Triwiyanto4 1Department of Environmental Health, Poltekkes Kemenkes Surabaya, Surabaya, Indonesia; 2Department of Medical Laboratory Technology, Poltekkes Kemenkes Surabaya, Surabaya, Indonesia ...
Rokhmalia F   +3 more
doaj  

Recent advances in two-dimensional nanomaterials for sustainable wearable electronic devices

open access: yesJournal of Nanobiotechnology
The widespread adoption of smart terminals has significantly boosted the market potential for wearable electronic devices. Two-dimensional (2D) nanomaterials show great promise for flexible, wearable electronics of next-generation electronic materials ...
Jing Hu, Mingdong Dong
doaj   +1 more source

FDG‐PET Associations With Disease Severity and Outcomes in NMDA‐Receptor IgG Autoimmune Encephalitis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Patients with N‐methyl‐D‐aspartate (NMDA) receptor‐immunoglobulin G (IgG) autoimmune encephalitis (NMDAR‐IgG AE) demonstrate occipital lobe hypometabolism on baseline brain fluorodeoxyglucose‐positron emission tomography (bFDG‐PET).
Jonathan K. Lee   +7 more
wiley   +1 more source

Location, Location, Location: Entrepreneurial Finance Meets Economic Geography [PDF]

open access: yes
Economic Geography maintains that economic activities are not randomly distributed across space. This paper examines the impact of industrial and regional characteristics on venture capital activities in the United States from 1995 until 2009. The unique
Emanuel Shachmurove   +1 more
core  

Location‐Specific Hematoma Volume Predicts Early Neurological Deterioration in Supratentorial ICH

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Early neurological deterioration (END) adversely affects outcomes in patients with intracerebral hemorrhage (ICH). This study aimed to determine the location‐specific hematoma volumes for END in supratentorial ICH patients. Methods We retrospectively analyzed supratentorial ICH patients presenting from two prospective cohorts.
Zuoqiao Li   +10 more
wiley   +1 more source

Venture Capital Meets Industrial Sector and Location [PDF]

open access: yes
This paper examines venture capital investment activity in the United States during the period 1995 to the first quarter 2009, taking into consideration both location and industry sector. The research question is whether industry and region are important
Emanuel Shachmurove   +1 more
core  

Математические модели развития и компенсации гипоксических состояний при ишемической болезни сердца у лиц летного состава [PDF]

open access: yes, 2019
The increase of pilots’ labor intensity caused by rapid development of flight technologies and increasing of complexity of combat missions faced by flight crew members increases the loads on organisms of flight personnel in general and in particular on
Аралова, Наталия Игоревна   +3 more
core  

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

Home - About - Disclaimer - Privacy